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Abstract 
Background: Seasonal Allergic Rhinitis is characterised by inflammation of the nasal mucosa upon exposure to com‑
mon aeroallergens, affecting up to 20–25 % of the population. For those patients whose symptoms are not controlled 
by standard medical treatment, allergen specific immunotherapy is a therapeutic alternative. Although several studies 
have shown changes in immunologic responses as well as long term tolerance following treatment with a sublingual 
allergy immunotherapy tablet, a detailed time course of the early mechanistic changes of local and systemic T and B 
cell responses and the effects on B cell repertoire in the nasal mucosa have not been fully examined.
Methods/design: This is a randomized, double‑blind, single‑centre, placebo controlled, two arm time course study 
based in the United Kingdom comparing sublingual allergy immunotherapy tablet (GRAZAX®, ALK‑Abello Horsholm, 
Denmark) plus standard treatment with placebo plus standard treatment. Up to 50 moderate to severe grass pollen 
allergic participants will be enrolled to ensure randomisation of at least 44. Further, we shall enrol 20 non‑atopic vol‑
unteers. Screening will be completed before eligible atopic participants are randomised to one of the two treatment 
arms in a 1 to 1 ratio. The primary endpoint will be the total nasal symptom score assessed over 60 min following 
grass pollen nasal allergen challenge after 12 months of treatment. Clinical assessments and/or mechanistic analyses 
on blood, nasal fluid, brushing and biopsies will be performed at baseline at 1, 2, 3, 4 (coinciding with the peak pollen 
season), 6 and 12 months of treatment. After 12 months of treatment, unblinding will take place. Those atopic partici‑
pants receiving active treatment will continue therapy for another 12 months followed by a post treatment phase of 
12 months. Assessments and collection of biologic samples from these participants will take place again at 24 and at 
36 months from the start of treatment. The 20 healthy, non‑atopic controls will undergo screening and one visit only 
coinciding with the 12 month visit for the atopic participants.
Discussion: The trial will end in April 2017. The trial is registered with ClinicalTrials.gov and the trial identifying num‑
ber is NCT02005627.
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Background
Seasonal allergic rhinitis (SAR) is an IgE-mediated 
inflammatory disease characterised by itching, sneez-
ing, nasal discharge and congestion. Early and late 
phase responses (EPR and LPR) occur upon exposure 
to common aeroallergens [1]. A substantial increase in 
the prevalence of SAR has been reported in industri-
alised countries, including Western Europe [1] and it is 
believed to affect up to 20–25 % of the population, with 
an estimated 80 million sufferers in Europe [1]. SAR has 
been shown to impact quality of life and impair learning 
performance in school children [2]. The current man-
agement of SAR consists of pharmacotherapy such as 
antihistamines and corticosteroids [3]. Also the avoid-
ance of aeroallergens such as staying indoors may be 
beneficial. For those patients whose symptoms are not 
controlled by standard medical treatment, allergen spe-
cific immunotherapy (SIT) is a therapeutic alternative 
[4]. In recent years, the sublingual route has been shown 
to be effective and in the case of GRAZAX® sublingual 
allergen specific immunotherapy (SLIT)-tablets to induce 
long-term remission [5]. Although adequately pow-
ered head to head studies have not been performed, the 
effects of subcutaneous allergen-specific immunotherapy 
(SCIT) and SLIT-tablet may be comparable, whereas 
SLIT-tablets are more convenient and have a better safety 
profile such that it may be administered in the patient’s 
home [6].
Changes in cellular as well as humoral responses play 
a role in the short term and long term efficacy of SIT. A 
shift in the ratio of T-helper 2 (Th2) and T-helper 1 (Th1) 
has been observed both peripherally [7], and in local tar-
get organs [8], preventing allergic response after SIT.
While some of the underlying mechanisms of SLIT-
tablets have not been studied in comparable detail to 
SCIT and remain unclear it is also assumed that the 
underlying immunological mechanisms may differ due 
to the different allergen administration routes. The oral 
mucosa is considered a site of natural immune tolerance. 
Previous findings suggest an interaction exists between 
Langerhans cells, epithelial cells, monocytes and oral 
DCs capable of producing IL-10, TGF-beta and activins 
and priming Treg cells [9].
In atopic individuals increased concentrations of aller-
gen-specific IgE in serum as well as target organs has 
been observed. Under SCIT, especially during the first 
few weeks of treatment, allergen-specific IgE increases 
even further, while there is a decrease during the seasonal 
peak [10]. On the other hand IgG subclasses, especially 
IgG1 and IgG4, increase. In competing with IgE they seem 
to prevent interaction with the allergen, possibly medi-
ated via the FCgammaRIIB receptor. Serum from these 
individuals inhibits IgE facilitated allergen binding (FAB) 
resulting in decreased T cell proliferation and reduced 
cytokine production and inhibition of basophil histamine 
release [11–14].
Congruently in SLIT-tablets, increases in allergen-
specific IgE may occur within weeks of start of treatment 
and again blunting of the IgE increase during the season 
similar to what has been shown in SCIT. Also levels of 
serum IgG4, even though lower compared to SCIT, and 
facilitated allergen presentation (FAP) inhibition was 
increased [5]. Effects on T-reg cells are inconsistent [15]. 
When using a simplified assay, allergen-IgE complexes 
bound to Fcepsilon RII on the surface of B cells were 
detected by flow cytometry (IgE-FAB) and serum inhibi-
tory activity for IgE-FAB increased under SLIT-tablets 
[16]. Our group has shown previously that successful SIT 
has been associated with increases in protective IgG4 and 
IgA2 responses and induction of antigen-specific regula-
tory T-cells (T-regs) [8, 17]. Furthermore, reduced levels 
of effector cells (mast cells, eosinophils, CD4+  T-cells) 
are recruited to the nasal epithelium after grass pol-
len allergen challenge [8, 16]. In an IL-10 and TGF-beta 
dependent manner, T-regs have been shown to sup-
press antigen-driven proliferative T cell responses and 
Th2 cytokine release [7, 18]. Also decreased eosinophil 
recruitment has been reported [19]. Elevated levels of 
IL-10 in parallel with clinical responsiveness preceding 
IgG4 was demonstrated in a SCIT compared to a placebo 
group with an increase as early as 2 weeks [19].
Despite these observed changes in cellular and 
humoral responses, a detailed time-course of SLIT-tab-
lets-induced immunological changes has not yet been 
performed.
Effects of SIT have been reflected in previous studies in 
changes of the nasal mediators such as the chemokines 
tryptase and eosinophilic cationic protein (ECP) [21]. In a 
cross sectional study SIT patients compared to untreated 
allergics had reduced levels of early phase tryptase and 
Trial registration: Primary Registry: ClinicalTrials.gov, Trial Identifying number: NCT02005627, Secondary identifying 
numbers: EudraCT number: 2013‑003732‑72 REC: 13/EM/0351, Imperial College London (Sponsor): 13IC0847, Protocol 
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Keywords: Sublingual immunotherapy tablet, GRAZAX, Allergy, Hay fever, Allergic rhinitis, Randomised, Double‑
blind, Placebo, CTIMP, Phleum pratense
Page 3 of 12Steveling et al. Clin Transl Allergy  (2015) 5:43 
eotaxin [22]. Other mediators such as the cytokine IL-5 
in nasal fluid were suppressed after SCIT [21]. We were 
able to show that in SIT patients a reduced nasal fluid 
concentration of IL-4, IL-9 and trends for reduced IL-13 
were present [22]. While peripheral IL-10 has been stud-
ied in SCIT, local changes of IL-10 after IT are less clear. 
While previous studies by Pilette have found fewer IL-10 
mRNA+ cells in the nasal mucosa of allergics [23], Ben-
son et al. reported increased levels of IL-10 [24]. In our 
recent cross sectional study no clear response of IL-10 in 
nasal fluid after NAC was seen [22]. Thus the time course 
in the first months of SLIT-tablets remains unclear and 
we aim to clarify this by examining a detailed early time 
course of chemokines and cytokines locally in SLIT-tab-
lets in this prospective study.
Recently the emergence of a novel innate immune cell 
family, type 2 innate lymphoid cells (ILC2), originally 
defined in murine models, has attracted interest. Mor-
phologically similar to lymphocytes they lack T-cell, 
B-cell, natural killer cell or other cell lineage markers [25]. 
Our group showed that peripheral ILC2s might also play 
a role in seasonal allergic rhinitis. An elevation of ILC2s 
was seen during the grass pollen season. In participants 
who received SIT levels were comparable to non-atopic 
controls and correlated with reported seasonal symptom 
severity [26]. Again a time course in a prospective SLIT-
tablet study has not been examined before.
Although several studies have shown changes in immu-
nologic responses following treatment with a SLIT-tab-
let, a detailed time course of local and systemic T and B 
cell responses and interactions, has yet to be fully deter-
mined. Moreover, although long-term clinical tolerance 
is associated with persistent blocking antibody responses 
in the periphery, the effect of SLIT-tablet on B cell rep-
ertoires in the target organ has not been fully examined. 
Recent advances in cloning of antibody genes from single 
B cells [27] and of sequencing of entire TCR and antibody 
repertoires present in biological samples [28] allow for 
detailed analysis of such repertoires in response to dis-
ease and subsequent treatment. Thus a number of ques-
tions in relation to SLIT-tablet can be addressed; Is there 
a clonal relationship between the induced changes in IgE 
and the IgG repertoires during SLIT-tablet, does the local 
IgE repertoire contract following tolerance induction? 
Is there infiltration or local expansion of protective B 
cells following treatment? Is persistent clinical tolerance 
associated with a restricted repertoire of high affinity 
blocking antibodies? In order to address these questions 
we aim to establish a detailed time course of the early 
response in T and B-cell responses and we aim to char-
acterise local and peripheral B cell repertoires in patients 
undergoing SLIT-tablet over the time course of 2  years 
under treatment and 1 year post treatment.
Hypotheses
We hypothesize that the analysis of the time course of 
SLIT-tablet over the first 4 months and up to 12 months 
will show early induction of T regulatory cells (T-regs) 
followed by later down regulation of Th2 responses and 
the emergence of ‘protective’ IgG/IgA antibodies both 
locally and in peripheral blood. This will correlate with 
surrogate clinical responses to treatment reflected by a 
reduction of the early phase response (EPR) following 
nasal allergen challenge (NAC) after 6 months and after 
12 months of treatment. We furthermore assume that the 
sequencing of T and B cell receptor repertoires during 
the course of SLIT-tablet will demonstrate the appear-
ance of distinct populations of grass pollen specific T and 
B cell clones.
Primary objectives
Our primary objectives are to understand the time 
course of early immunological changes as well as long-
term changes in B cell repertoire under grass pollen AIT 
in SAR corresponding to clinical surrogate markers of 
AIT efficacy with a reduction of the EPR following NAC.
Secondary objectives
We aim to assess the early time course of changes in dif-
ferent clinical surrogate markers for AIT efficacy includ-
ing both early-phase (0–60  min) and late-phase (8  h) 
measurements following nasal and intradermal allergen 
challenge. We shall also record medication and symp-
tom scores during the pollen season. We are furthermore 
interested in establishing a molecular sensitisation pro-
file in untreated and treated allergic individuals. We will 
document the presence and severity of any local and sys-
temic side effects of AIT treatment.
Trial design
This is a randomized, double-blind, single-centre, pla-
cebo-controlled study comparing SLIT-tablet plus stand-
ard treatment versus sublingual placebo plus standard 
treatment. The allocation of the atopic participants will 
be 1:1. We assume superiority for the SLIT-tablet over 
placebo.
Methods
Study setting
The study will be conducted at the Royal Brompton Hos-
pital (RBH), an academic hospital affiliated to the Impe-
rial College London as sponsor (UK). We plan to enrol 
up to 50 participants in order to randomise at least 44 
atopic participants. Additionally, we shall recruit 20 
healthy, non-atopic volunteers. To assess a detailed time 
course of early immunological changes under SLIT-
tablet clinical assessments and mechanistic analyses on 
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blood, nasal fluid, brushing and biopsies will be per-
formed at baseline at 1, 2, 3, 4 (coinciding with the peak 
pollen season), 6 and 12  months of treatment (Fig.  1). 
After 12 months of treatment, unblinding will take place. 
Those atopic participants receiving SLIT-tablet will con-
tinue therapy for another 12 months followed by a post 
treatment phase of 12 months. Assessments and sample 
collection from these participants will take place again 
at 24 and at 36  months from the start of treatment. 
The non-atopic volunteers will serve as a control for 
parameters collected at the 12  months’ time point. All 
participants will be provided with anti-allergic rescue 
medication throughout the pollen season 2014. Con-
sent will be obtained in line with the Declaration of Hel-
sinki. The Nottingham Ethics Committee has approved 
this study (reference 13/EM/0351). The duration of the 
trial is 3  years. The trial will end in March 2017 when 
the last subject undergoes the last study visit completing 
the open label follow up of 2 years after the 12 months 
blinded phase (Fig. 2).
Eligibility criteria
Inclusion criteria of atopic participants:
1. Adults age 18–65 years.
2. A clinical history of grass pollen-induced allergic rhi-
noconjunctivitis for at least 2 years with peak symp-
toms in mid-May to mid-July.
3. A clinical history of moderate to severe rhinocon-
junctivitis symptoms with or without mild seasonal 
asthma interfering with usual daily activities or with 
sleep.
4. A clinical history of rhinoconjunctivitis with or with-
out mild seasonal asthma that remains troublesome 
despite treatment with either antihistamines or nasal 
corticosteroids during the grass pollen season.
5. Positive skin prick test response, defined as wheal 
diameter ≥3 mm, to timothy grass pollen.
6. Positive specific IgE, defined as IgE immuno-
CAP ≥0.7 ISU, against timothy grass pollen.
7. For women of childbearing age, a negative urine 
pregnancy test at the time of screening and willing-
ness to use an effective form of contraception for the 
duration of involvement in the study.
8. The ability to give informed consent and comply with 
study procedures.
9. A positive grass pollen NAC test at screening as 
defined by a total nasal symptom score (TNSS) of at 
least 7/12 after 5 min with an allergen dose of 5000 
BU/ml (in case at least 20 % of the screened individu-
als report a TNSS of ≤5 the cut-off will be lowered to 
a minimum of 5/12).
Inclusion criteria of non-atopic participants:
1. Adults age 18–65 years.
2. Negative skin-prick test response to timothy grass 
pollen and panel of aeroallergens.
3. Negative specific IgE, defined as IgE immuno-
CAP <0.35 ISU, against timothy grass pollen.
Fig. 1 Study plan for atopic participants during the blinded phase of the treatment. V visit, n number
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4. For women of childbearing age, a negative urine 
pregnancy test at the time of screening and willing-
ness to use an effective form of contraception for the 
duration of involvement in the study.
5. The ability to give informed consent and comply with 
study procedures.
Exclusion criteria of atopic participants:
 1. Previous grass pollen allergen immunotherapy.
 2. Prebronchodilator FEV1 <70 % of predicted value at 
screening (out of grass-pollen season).
 3. A clinical history of symptomatic allergic rhinitis and/or 
asthma caused by an allergen to which the participant 
is regularly and perennially exposed (e.g. cat dander).
 4. Perennial asthma requiring regular inhaled corticos-
teroids.
 5. Seasonal symptoms outside the grass-pollen sea-
son [e.g. hay fever during March–April suggestive 
of birch pollen allergy  (during screening a panel of 
common aeroallergens such as house dust mite and 
birch pollen will be performed to allow exclusion of 
sensitisations to other aeroallergens of clinical rel-
evance)].
 6. History of emergency visit or hospital admission for 
asthma in the previous 12 months.
 7. History of chronic obstructive pulmonary disease.
 8. History of recurrent acute sinusitis.
 9. History of chronic sinusitis.
 10. At screening visit, current symptoms of, or treat-
ment for, upper respiratory tract infection.
 11. Current smokers or a history of ≥5 pack years.
 12. History of life-threatening anaphylaxis or angi-
oedema.
 13. Ongoing systemic immunosuppressive treatment.
 14. The use of any investigational drug within 30 days of 
the screening visit.
 15. The presence of any medical condition that the 
investigator deems incompatible with participation 
in the study.
 16. History of fish allergy with positive skin test and/or 
positive specific IgE test to vertebrate/finned fish (due 
to potential fish allergen exposure in SLIT-tablet).
 17. Contraindications taking GRAZAX®.
Fig. 2 Study schedule and participant timeline. GE global evaluation score
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Exclusion criteria of non-atopic participants:
 1. Previous grass pollen allergen immunotherapy.
 2. Prebronchodilator FEV1 <70 % of predicted value at 
screening (out of grass-pollen season).
 3. A clinical history of symptomatic allergic rhinitis 
and/or asthma caused by an allergen to which the 
participant is regularly and perennially exposed (e.g. 
cat dander).
 4. Perennial asthma requiring regular inhaled corticos-
teroids.
 5. Seasonal symptoms outside or during the grass-pol-
len season.
 6. History of emergency visit or hospital admission for 
asthma in the previous 12 months.
 7. History of chronic obstructive pulmonary disease.
 8. History of significant recurrent acute sinusitis.
 9. History of chronic sinusitis.
 10. At screening visit, current symptoms of, or treat-
ment for, upper respiratory tract infection.
 11. Current smokers or a history of ≥5 pack years.
 12. History of life-threatening anaphylaxis or angi-
oedema.
 13. Ongoing systemic immunosuppressive treatment.
 14. The use of any investigational drug within 30 days of 
the screening visit.
 15. The presence of any medical condition that the 
investigator deems incompatible with participation 
in the study.
Intervention
SQ® grass SLIT-tablet (GRAZAX®, ALK Abello Horsholm, 
Denmark) is a fast-dissolving tablet that is registered 
throughout Europe and North America for sublingual 
use in patients aged 5–65  years [20, 29, 30]. The tablet 
is administered sublingually and daily for a minimum of 
2  months before and during the grass pollen season. In 
a double-blind trial of GRAZAX® that included a 2 year 
follow up period efficacy was maintained for 2 post treat-
ment years [29–32]. Even though SLIT-tablet has been 
shown to be safer than the injection route it is recom-
mended that the first dose of GRAZAX® is adminis-
tered in the clinic. Subsequent doses are taken daily by 
the patient. Local side effects of itching and swelling in 
the mouth are common, occurring in up to 60 % of indi-
viduals within minutes and resolving within 1  h with a 
median half-life of approximately 10 days [29–31]. These 
side effects are, in general, well tolerated and require 
no treatment. In a recent large trial involving over 600 
patients, the withdrawal rate was 5 % as compared to 3 % 
in placebo-treated patients [29, 30]. More severe local 
and systemic reactions have been reported, but they are 
excessively rare and no fatalities have occurred [33].
Formulation and packaging
GRAZAX® is formulated as a freeze-dried oral lyophili-
sate disintegrating tablet for sublingual use. The active 
pharmaceutical ingredient is a standardized allergen 
extract derived from extraction and purification of grass 
pollen from timothy grass (Phleum pratense). The recom-
mended dosage is one tablet containing 75,000 SQ-T®. 
The non-active ingredients consist of fish gelatin, manni-
tol, sodium hydroxide and water. The placebo is a tablet 
whose composition is identical to the GRAZAX® tab-
let with the only exception being exclusion of the active 
pharmaceutical ingredient. GRAZAX® and placebo tab-
lets will be supplied in blister packs by ALK-Abello and 
packed into monthly dispensing packages containing 
40 tablets. Two packages will be dispensed once every 
2 months.
Dosing regimen
The first dose will be administered under an hour of 
observation in clinic followed by daily home admin-
istration. After unblinding, participants who received 
active treatment will receive SLIT-tablets for another 
12 months. The participants who received placebo will be 
offered 24 months of SLIT-tablets.
Study medication accountability
The investigator is required to maintain adequate records 
of the disposition of the investigational product. An 
account of any drug accidentally or deliberately destroyed 
will be kept as a file note in the trial master file. Partici-
pants will be asked to return unused tablets at each study 
visit. The unused tablets will be counted by pharmacy. 
Participants will record their tablet intake on a daily 
diary.
Concomitant medications
During the pollen season the following medications will 
be provided: antihistamine (desloratidine 5  mg, up to 
once daily), nasal corticosteroid spray (fluticasone propi-
onate aqueous nasal spray, 50 mcg per spray, up to 2 puffs 
twice daily) and ophthalmic antihistamine (olopatadine 
eye drops, 1  mg/ml, up to 1 drop per eye twice daily). 
We will assess the use of rescue medication by a weekly 
medication score. Oral corticosteroids (prednisolone 
30 mg for 3–5 days), short-acting beta-agonists, inhaled 
corticosteroids and combination long-acting beta-ago-
nists-steroids will only be provided to the participants 
after consultation with the investigators. Medication 
washout periods prior to NACs and biopsies need to be 
followed. During the study β-blockers, calcium channel 
blockers, tricyclic antidepressants, monoamine oxidase 
inhibitors or anti-IgE monoclonal antibody treatment are 
prohibited.
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Outcomes
Primary clinical endpoint
•  The TNSS recorded over 60 min following grass pollen 
NAC.
Secondary clinical endpoints
  • EPR of PNIF following NAC.
  • LPR to intradermal allergen.
  • EPR to intradermal allergen.
  • Retrospective visual analogue scale (VAS) after the 
pollen season 2014.
  • Retrospective global evaluation (GE) score after the 
pollen season 2014.
Exploratory clinical endpoints
  • Combined weekly symptom and medication score 
over the course of the grass pollen season from May 
to July 2014.
  • Mini Rhinoconjunctivitis Quality of life (mRQLQ) 
symptom score over the course of the pollen season 
2014.
  • Presence and severity of symptoms due to sublingual 
treatment.
  • VAS over the course of the 2014 grass pollen season 
from May to July 2014.
  • EPR following NAC at baseline, 6  months and 
12 months.
Secondary mechanistic endpoints
  • Grass allergen-induced basophil activation.
  • Proportion of allergen-specific phenotypic Treg cells 
in peripheral blood.
  • The inhibitory bioactivity of sera against allergen-IgE 
complex formation and binding to B-cell.
  • The frequency of type 2 innate lymphoid cells.
  • Concentration of serum total IgE and grass pollen 
specific IgG4 and IgE level.
  • Cytokine concentration in peripheral blood.
  • Concentration nasal fluid grass pollen specific IgG4 
and IgE level.
  • Cytokine RNA in nasal brushing.
  • Single cell antibody cloning of local nasal B cells.
  • T and B cell receptor sequencing.
Sample size
Inclusion of 20 participants per group will give greater 
than 90 % power (p = 0.05) to detect a 40 % reduction in 
the nasal EPR after NAC (see Durham et al. [8]). Based 
on more recent studies (Scadding et  al., unpublished 
data; mean 4.63, standard deviation 1.65 for area under 
the curve (AUC) 0-60 min post NAC in 14 allergic vol-
unteers), inclusion of 13 patients per group will provide 
80  % power to detect a 40  % reduction in AUC after 
NAC, whereas inclusion of 22 patients per group will 
provide 80 % power to detect a 30 % reduction. We will 
include 20 healthy, non-atopic controls to match the two 
atopic groups.
Recruitment, screening and enrolment
Recruitment of the participants will be within the RBH, 
Imperial College London, and via local media. Potential 
atopic participants will be invited to visit the trial website 
(http://www.hayfeverstudy.com) for registration. They 
will be invited to attend the Research Unit at the RBH for 
a formal screening visit.
Assignment of interventions
Allocation sequence generation
The randomisation list was produced by a statistician 
using Stata 10.1 without stratification or blocks and with 
an allocation of 1:1.
Allocation concealment mechanism
The sequence of the randomisation numbers is kept in 
sealed envelopes independent of the investigators.
Implementation
The packaging company will label the tablet packages 
according to the randomisation list. Single sealed enve-
lopes containing the participants’ randomisation code are 
located at the RBH pharmacy.
Unblinding
Blinding of the investigators, outcome assessors, phar-
macists, data analysts and trial participants will be 
maintained throughout the first 12 months of the study. 
Adverse events (AEs) that are considered serious, unex-
pected and at least possibly related to the medication 
would have to be unblinded. The study will be unblinded 
by the trial statistician after the final visit of the primary 
endpoint assessment at 12 months of treatment.
Withdrawal of participants/stopping rules and urgent safety 
measures
Participants have a right to withdraw at any time and 
may be withdrawn at the investigator’s discretion. Rea-
sonable effort should be made to contact any participant 
lost to follow-up. The information collected before the 
withdrawal will be included in analysis. Participants will 
not be replaced. The PI will have the authority to deviate 
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from the protocol if doing so relates to the immediate 
safety of a participant, where continuing to follow proto-
col would put that participant at risk. If any of the follow-
ing criteria are met, study enrolment and study therapy 
will be suspended: death in any participant, where death 
is attributed in any way to study therapy or interven-
tion; grade 4 anaphylaxis as defined by the World Allergy 
Organization (WAO) [34]. Study therapies will be dis-
continued for any of the following reasons: two or more 
occurrences of grade 3 or above systemic allergic reac-
tions as defined by the WAO [34]; any AE that presents 
an unacceptable consequence to the participant; an ill-
ness that requires treatment not consistent with protocol 
requirements; inability to comply with the study protocol 
and pregnancy.
Data collection, management and analysis
Data collection methods of the primary efficacy parameter
The primary efficacy parameter will be the EPR 
measured by the TNSS at 0, 5, 15, 30 and 60  min fol-
lowing grass pollen NAC in SLIT-tablet-, versus 
placebo-treated atopic participants at 12  months of 
treatment. The NAC will be performed with Aquagen 
SQ (ALK 225) Timothy grass pollen, Phleum pratense, 
ALK-Abelló freeze dried extract (Cat. no. 1001862, 
ALK-Abelló, Denmark). Fresh extracts will be reconsti-
tuted in albumin-based diluent (ALK-Abelló) on a twice 
weekly basis at a concentration of 100,000 SQ-U/30,000 
BU per ml. On a daily basis, a fresh dilution of 5000 BU/
ml in normal saline will be prepared and added to a 
nasal applicator device (Bidose, Aptar Pharma/Pfeiffer, 
Germany), (100  µl/pump application). A single spray 
will be applied to each nostril.
Data collection methods of the secondary clinical efficacy 
parameters
  • PNIF measured at 0, 5, 15, 30 and 60  min (EPR) 
following grass pollen NAC at baseline and at 
12 months.
  • Mean LPR to intradermal testing recorded as the 
mean diameter of the swelling (longest diameter plus 
perpendicular diameter, exclude pseudopods) meas-
ured after 8  h of allergen challenge at baseline and 
after 12 months of treatment. Intradermal skin tests 
are performed by injecting 1 BU (0.02 ml of 50 BU/
ml) of allergen into the skin of the outer surface of 
the forearms.
  • Mean EPR to intradermal testing recorded after 
15  min of allergen challenge at baseline and after 
12 months of treatment.
  • VAS after the pollen season 2014 (‘How has your 
hayfever been overall during the last pollen season?’); 
single measurement and delta (comparing baseline 
with after pollen season time point 2014).
  • GE score (‘How has your hayfever been during the 
last pollen season compared to the previous season?’) 
after the pollen season 2014.
Exploratory endpoints
The endpoints listed below will compare the follow-
ing groups using the same statistical methodology as 
described for the primary endpoint: SLIT-tablet versus 
placebo.
  • Symptoms and medication scores will be self-
assessed weekly during the pollen season from May 
2014 until end of July 2014 by the atopic participants. 
The symptom score will encompass nose and eye 
symptoms recorded on a scale from 0 to 3 (with a 
score of 0 indicating no symptoms, 1, 2 and 3 indi-
cating mild, moderate and severe symptoms respec-
tively). The maximum score is therefore 18. Par-
ticipants will be asked to use the rescue medication 
received by us on an as required basis only, starting 
with the antihistamines (tablets and/or eye drops) 
and if this does not suffice adding treatment with 
nasal spray. In case this still does not relieve their 
symptoms they will be advised to contact the trial 
team to start prednisolone 30 mg 3–5 days. Medica-
tion use will be recorded in weekly questionnaires 
by participants and a medication score will be calcu-
lated: desloratadine, 5 mg, up to 1 tablet daily and/or 
olopatadine eye drops, 1.0  mg/ml, up to 1 drop per 
eye twice daily (1 point per day); fluticasone nasal 
spray, 50 mcg per spray, up to 2 sprays per nostril 
twice daily (2 points per day); and prednisone, 5 mg 
per tablet, up to 6 tablets per day (3 points per day). 
The maximum daily medication score will be 3. The 
maximum weekly score will be 21. 21 will be divided 
by 7 and multiplied by 6, which gives us a maximum 
score of 18, to allow a comparison between symptom 
and medication scores, since maximum scores for 
symptoms and medications are different in magni-
tude, as recommended by WAO guidelines. A com-
bined symptom and medication score will be calcu-
lated by dividing both scores by 6, summarize of the 
results and divide by 2 [35]. Composite scores in each 
treatment group during the pollen season (beginning 
of May to end of July) and during the peak pollen 
season (approximately mid-June, defined as the max 
14  day rolling average pollen count during the sea-
son) will be compared.
  • MiniRQLQ scores will be collected weekly during the 
pollen season. Composite scores in each treatment 
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group during the peak pollen season (beginning of 
May to end of July) will be compared. Furthermore 
the maximum RQLQ will be compared.
  • Symptoms and severity of symptoms after intake 
of the daily tablets will be recorded on a daily diary 
cards. The type of symptom (itchy mouth, swelling of 
the mouth or other) and the WAO Grade of the local 
symptoms will be calculated daily [36]. The duration 
of the symptoms in days and the duration of symp-
toms in minutes will be specified.
  • VAS of overall hay fever symptoms in the last week 
will be collected weekly during the pollen season. 
Composite scores in each treatment group during the 
peak pollen season (beginning of May to end of July) 
as well as the maximum will be assessed.
  • The TNSS measured at 0, 5, 15, 30 and 60 min (EPR) 
following grass pollen NAC at baseline, at 6 and at 
12  months will be assessed similar to the primary 
endpoint.
Secondary mechanistic parameters
Grass pollen specific immunological markers in serum, 
nasal fluid and nasal brushings will be evaluated at base-
line, after 1, 2, 3 months, during the peak pollen season 
(at 4  months) and after 12  months of treatment. Blood 
will be collected via venepuncture during the study visit.
  • Basophil activation will be assessed by expression 
of the surface markers CD107a, CD63 and CD203c 
on basophils (CRTH2+ CD3− CD303− cells) in the 
whole blood via flow cytometry.
  • The inhibitory bioactivity of sera against allergen-IgE 
complex formation and binding to B-cell is evaluated 
by using IgE-facilitated allergen binding (FAB) assay.
  • The frequency of type 2 innate lymphoid cells is 
measured by immunostaining with fluorochrome 
monoclonal antibodies and determined using multi-
color flow cytometric analysis.
  • Concentration of serum total IgE and grass pol-
len specific IgE and IgG4 level will be measured on 
a CAP FEIA system (Thermo-Fisher, Uppsala, Swe-
den).
  • PBMCs are isolated and cultured for 6  days and 
cytokine concentrations specifically IL-10 will be 
measured in culture supernatants by means of 
ELISA.
  • The collection and preparation of nasal fluid will 
be performed with a sterile synthetic polyure-
thane sponge (Zuschnitt Schaumstoff RG27 grau, 
Gummi-Welz GmbH & Co, Germany, ISO 5999, 
1982 sponge), inserted into each nostril. Sponges 
will be left in place for 5 min before removal to allow 
absorption of nasal secretions, and then transferred 
to centrifuge tubes with indwelling 0.22 μm cellulose 
acetate filters (Costar Spin-X, Catalogue no. 8161, 
Corning, NY, USA). Tubes will be kept briefly on ice, 
then 75 µl of assay buffer (Millipore; Catalogue No. 
L-AB) will be added on top of the sponge into each 
tube before being centrifuged at 4500 RCF for 15 min 
at 4  °C. The volume of fluid collected will be calcu-
lated, aliquoted into Micrewtubes® (cat no.: T336-2S, 
Simport, Beloeil, Canada) and stored at −80  °C. 
Concentration of nasal fluid grass pollen specific 
IgG4 and IgE level will be measured on a CAP FEIA 
system (Thermo-Fisher, Uppsala, Sweden). Nasal 
fluid analyses for cytokines and chemokines using 
a human cytokine/chemokine magnetic bead panel 
96-well plate assay (Milliplex Map Kit; Millipore) and 
a Luminex xMAP Magpix platform (Millipore) will 
be performed.
  • Biopsies will be performed at baseline, during the 
peak pollen season, after 12 months, 24 months of 
treatment and 12  months post treatment. Single 
cell antibody cloning will be performed accord-
ing to standardized methods developed by the 
commercial suppliers (http://www.irepertoire.
com or http://www.adaptivebiotech.com). Clon-
ing of antibody heavy and light variable genes 
from single B cells will be done essentially as previ-
ously described [27]. Isotype switched B cells will 
be isolated from enzymatically dissociated nasal 
biopsy tissue by fluorescence activated cell sort-
ing (FACS). Matched heavy and light chain tran-
scripts will be amplified from individually sorted 
single B cells by RT-PCR. PCR products will be 
sequenced and selected antibodies will be cloned 
and produced by recombinant expression. Allergen 
specificity will be determined by ISAC microar-
ray and antibody—allergen binding affinities will 
be determined by surface plasmon resonance. In 
parallel, RNA will be isolated from a second nasal 
biopsy and from PBMC and converted to cDNA. 
Heavy (IgA, IgG, IgM and IgE) chain variable 
region transcripts will be amplified using isotype-
specific PCR and sequenced in parallel using high-
throughput Illumina MiSeq sequencing.
The start of the pollen season will be defined retrospec-
tively for the purpose of the analysis. Start of the pollen 
season is defined as the first 3 consecutive days with pol-
len count >10 grains/cm3, end of season is defined as the 
first consecutive days with pollen count <10 grains/cm3, 
start of peak pollen season is defined as the first 3 con-
secutive days with pollen count  >30 grains/cm3, end of 
peak pollen season is defined as the first consecutive days 
with pollen count <30 grains/cm3.
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Data management
Statistical analysis
The statistical analysis plan will be finalised by the 
trial statistician prior to database lock. Primary anal-
ysis of treatment effect will be conducted under the 
intention-to-treat (ITT) principle defined as all ran-
domized participants. The per-protocol (PP) sample 
will be defined as ITT sample participants in whom 
the primary endpoints were assessed. The Safety sam-
ple (SS) will be defined as all enrolled participants. 
The following groups will be compared: SLIT-tablet 
versus placebo; SLIT-tablet versus placebo versus non-
atopic controls.
Analysis of the primary endpoint
This longitudinal data will be analysed using approaches 
that model the correlation structure such as models for 
the mean response and random coefficient models.
Secondary and exploratory endpoints
All secondary analyses will be treated as supportive. P 
values will be presented for the secondary endpoints but 
will not be adjusted for multiplicity.
Secondary mechanistic endpoints
Grass pollen specific immunological markers in serum, 
nasal fluid and nasal brushings and nasal biopsies at 
12 months of treatment will be evaluated.
Monitoring
Data monitoring
The data will be monitored regularly twice in the first 
year and once yearly in the years following the first year 
by Imperial College, the sponsor of this trial. Monitoring 
by the REC and MHRA may also occur.
Procedures for recording and reporting adverse events
AE will be recorded and severity and relation to study 
participation will be assessed. SAE data will be collected, 
faxed to the Sponsor and transcribed to eCRF. Please also 
refer to Additional file 1.
Adverse events that do not require reporting
These include the following:
  • Seasonal symptoms such as itching, sneezing and 
wheezing.
  • Not bothersome local symptoms after SLIT-tablet 
intake.
  • Non-bothersome reactions to the non-invasive nasal 
secretion collection.
  • Not bothersome allergic reactions after Intradermal 
skin tests.
  • Bleeding responding to local finger pressure and 
discomfort responding to paracetamol after nasal 
biopsy.
Ethics and dissemination
The study has been approved by the Nottingham Ethics 
Committee (reference 13/EM/0351).
Amendments
Study amendments have been approved by the REC, the 
R and D Office and the MHRA where appropriate.
Consent
A participant information sheet will be provided to each 
person to read at least 24 h prior to the screening visit. 
Written IC will be obtained prior to any study specific 
procedures taking place.
Confidentiality
Data will be handled, computerised and stored in accord-
ance with the Data Protection Act, 1998.
Access to data
Database access will be restricted through passwords to 
the authorised research team.
Data sign off
The PI will provide an electronic signature for each 
patient eCRF once all queries are resolved and immedi-
ately prior to database lock.
Discussion
This protocol will allow us to investigate the time course 
of the first 4 months after start of SLIT-tablet. Further we 
will have the opportunity to look at B cell repertoire after 
12, 24 and 36 months of treatment. The trial will end in 
April 2017.
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